<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ophthalmology</journal-id><journal-title-group><journal-title xml:lang="ru">Офтальмология</journal-title><trans-title-group xml:lang="en"><trans-title>Ophthalmology in Russia</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1816-5095</issn><issn pub-type="epub">2500-0845</issn><publisher><publisher-name>Ophthalmology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18008/1816-5095-2017-2-170-174</article-id><article-id custom-type="elpub" pub-id-type="custom">ophthalmology-380</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРГАНИЗАЦИЯ ОФТАЛЬМОЛОГИЧЕСКОЙ ПОМОЩИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Eye care</subject></subj-group></article-categories><title-group><article-title>ВЫЖИВАЕМОСТЬ ПАЦИЕНТОВ  ПОСЛЕ  УДАЛЕНИЯ  ГЛАЗНОГО  ЯБЛОКА ПО ПОВОДУ УВЕАЛЬНОЙ  МЕЛАНОМЫ  В ПЕРМСКОМ КРАЕ</article-title><trans-title-group xml:lang="en"><trans-title>THE SURVIVAL RATE  OF PATIENTS FOLLOWING UVEAL MELANOMA  EYEBALL REMOVAL IN PERM  REGION</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гаврилова</surname><given-names>Т. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Gavrilova</surname><given-names>T. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гаврилова Татьяна Валерьевна — доктор медицинских наук, профессор.</p><p>Ул. Петропавловская, 26, Пермь,  614000</p></bio><bio xml:lang="en"><p>Gavrilova Tat’jana V. — MD, professor.</p><p>Petropavlovskaya str. 26, Perm, 614000</p></bio><email xlink:type="simple">gavrilova.tv@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Черешнева</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Chereshneva</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Черешнева Маргарита Владимировна — доктор медицинских наук, профессор.</p><p>Ул. Первомайская,  91, Екатеринбург, 620041</p></bio><bio xml:lang="en"><p>Chereshneva  Margarita  V.  — MD,  professor.</p><p>May Day str. 91, Yekaterinburg, 620041</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бактикова</surname><given-names>Л. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Baktikova</surname><given-names>L. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Бактикова Лейсан Ильнуровна  — ординатор.</p><p>Ул. Петропавловская, 26, Пермь,  614000</p></bio><bio xml:lang="en"><p>Baktikova Lejsan I. — resident.</p><p>Petropavlovskaya str. 26, Perm, 614000</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО Пермский  государственный медицинский  университет  им. академика Е.А. Вагнера Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Perm State Medical Universit y named  after  Academician  E. A. Wagner</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУН Институт иммунологии и физиологии  Уральского  отделения  Российской  академии  наук</institution><country>Россия</country></aff><aff xml:lang="en"><institution>The Institute  of Immunology and Physiology Ural Branch  of the Russian  Academy of Sciences</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>03</day><month>07</month><year>2017</year></pub-date><volume>14</volume><issue>2</issue><fpage>170</fpage><lpage>174</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Гаврилова Т.В., Черешнева М.В., Бактикова Л.И., 2017</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="ru">Гаврилова Т.В., Черешнева М.В., Бактикова Л.И.</copyright-holder><copyright-holder xml:lang="en">Gavrilova T.V., Chereshneva M.V., Baktikova L.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.ophthalmojournal.com/opht/article/view/380">https://www.ophthalmojournal.com/opht/article/view/380</self-uri><abstract><p>Цель исследования — анализ  выживаемости  пациентов, проживающих  в  Пермском крае  после  удаления  глазного  яблока по поводу увеальной  меланомы.</p><sec><title>Пациенты и методы</title><p>Пациенты и методы. Проведен  ретроспективный анализ  за  10 лет (2005–2014 гг.) историй болезней и амбулаторных  карт  108  пациентов, находившихся  на лечении  в офтальмологических отделениях  Пермского  края, которым  была проведена энуклеация  глазного  яблока  по поводу увеальной  меланомы.</p></sec><sec><title>Результаты</title><p>Результаты. За  исследуемый  период  у 108 пациентов  в возрасте 17–89 лет (средний возраст — 61,61,6 год) было удалено 108 глазных яблок  по поводу увеальной меланомы, женщины  составляли 56,5%,  мужчины — 43,5%.  Практически слепыми  были 63,8% глаз,  на  остальных  глазах острота  зрения  была от 0,005 до 1,0. Меланома локализовалась в хориоидее в 79,6% случаев,  в цилиарном теле  — в 10,2%, в радужке  — в 4,6%, в цилиарном  теле  и радужке  — в 5,6%. Всем  пациентам  была  проведена энуклеация  глазного  яблока, первичная — у  106 человек, у  двух пациентов  — после  проведения безуспешных  органосохранных  методов  лечения. Гистологически  смешанноклеточная форма  была  отмечена в 68,5%,  веретеноклеточная — в 28,7%,  эпителиоидноклеточная — в 2,8%. Выяснена  судьба  99 (91,7%) пациентов. Срок наблюдения  составил от 6 месяцев до 10 лет  после  удаления  глазного яблока. Из них за  исследуемый  период умерли 27 (27,3%) человек. Пятилетняя выживаемость составила 79,8%  при средней продолжительности жизни  3,4 года.  Причина смерти  установлена у  19 человек (70,4%), при этом  связь с онкологическими заболеваниями установлена у  6, с не онкологическими — у  13.</p></sec><sec><title>Заключение</title><p>Заключение. Необходимо  пожизненное наблюдение  данных пациентов  офтальмологом и онкологом  по месту жительства. Врачи амбулаторно-поликлинического звена  должны  проявлять онкологическую  настороженность при работе  с пациентами  любого возраста для  более  ранней  диагностики  новообразований органа  зрения.</p></sec></abstract><trans-abstract xml:lang="en"><p>Objective  — analysis  of survival  rate   among   the  patients with uveal  melanoma eyeball  removal  in Perm   Region.  patients  and methods. Retrospective  analysis  of medical  documentation of 108 patients treated in ophthalmologic  departments in the  cit y  of Perm  has  been  carried out.  Patients have  undergone the  surgery for uveal melanoma eyeball enucleation (2005–2014).</p><sec><title>Results</title><p>Results. Analytic period  involved 108 uveal melanoma eyeball removal  in 108 patients aged  17–89 (61,61,6 years  in average). There  were 61 (56,5%) women and 47 (43,5%) men.  Practical blindness  was identified in 63,8% eyes,  and in remaining  eyes it was detected in 0,005–1,0 cases. Melanoma  was localized in choroid in 79,6%; ciliary body — 10,2%; iris — 4,6%; and ciliary body and iris — 5,6%. Histology revealed  mixed cell form  in 68,5% cases; sarcomatoid form  — 28,7%; epithelioid cell form  — 2,8%. The outcome was determined in 99 (91,7%) patients. Follow-up period  was  from 6 months to 10 years  after  enucleation. Among those  27 (27,3%) patients died within the analytic period.  Five-year survival rate  was observed in 79,8% patients with average lifespan 3,4 yrs. Cause  of death  was established in 19 (70,4%) individuals. Association  with oncologic diseases was determined in 6 (31,6%), and non-oncologic in 13 (68,4%) subjects.</p></sec><sec><title>Conclusion</title><p>Conclusion. At the place of residence life-long observation by ophthalmologist and oncologist  is essential for these patients. Outpatient  physicians should have oncologic alertness while working with patients of any age for early diagnosis  of eye neoplasm.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>увеальная меланома</kwd><kwd>энуклеация</kwd><kwd>выживаемость</kwd><kwd>метастазы</kwd><kwd>продолжительность жизни</kwd></kwd-group><kwd-group xml:lang="en"><kwd>uveal melanoma</kwd><kwd>enucleation</kwd><kwd>survival rate</kwd><kwd>metastases</kwd><kwd>long-terms results</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Lutz J.M., Gree I.M., Foss A.J. Risk factors for intraocular melanoma and occupational exposure. Br. J. Ophthalmol. 1999;83(10):1190‑1193.</mixed-citation><mixed-citation xml:lang="en">Lutz J.M., Gree I.M., Foss A.J. Risk factors for intraocular melanoma and occupational exposure. Br. J. Ophthalmol. 1999;83(10):1190‑1193.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Brovkina A. F., Vаl’skij V. V., Gusev G. A. [Guide for physicians. Ophthalmooncology] M.: Medicina, 2002. (in Russ.).</mixed-citation><mixed-citation xml:lang="en">Brovkina A. F., Vаl’skij V. V., Gusev G. A. [Guide for physicians. Ophthalmooncology] M.: Medicina, 2002. (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Brovkina A.F., Astahov Ju.S. [Manual of clinical ophthalmology]. M.: Medical information agency, 2014. (in Russ.).</mixed-citation><mixed-citation xml:lang="en">Brovkina A.F., Astahov Ju.S. [Manual of clinical ophthalmology]. M.: Medical information agency, 2014. (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Brovkina A.F. [Choroidal melanomas: problems, controversial questions] Sovremennye aspekty lechenija melanom horioidei: problemy i diskussionnye voprosy [Annals of ophthalmology]. Vestnik oftal’mologii. 2006;1:13‑15. (in Russ.).</mixed-citation><mixed-citation xml:lang="en">Brovkina A.F. [Choroidal melanomas: problems, controversial questions] Sovremennye aspekty lechenija melanom horioidei: problemy i diskussionnye voprosy [Annals of ophthalmology]. Vestnik oftal’mologii. 2006;1:13‑15. (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Saakjan S.V., Panteleeva O.G., Shirina T.V. [Metastatic disease characteristics and survival in patients with uveal melanoma depending on primary tumor treatment]. Osobennosti metastaticheskogo porazhenija i vyzhivaemosti bol’nyh s uveal’noj melanomoj v zavisimosti ot provedennogo lechenija [Russian ophthalmological journal]. Rossijskij oftal’mologicheskij zhurnal. 2012;5(2):55‑7 (in Russ.).</mixed-citation><mixed-citation xml:lang="en">Saakjan S.V., Panteleeva O.G., Shirina T.V. [Metastatic disease characteristics and survival in patients with uveal melanoma depending on primary tumor treatment]. Osobennosti metastaticheskogo porazhenija i vyzhivaemosti bol’nyh s uveal’noj melanomoj v zavisimosti ot provedennogo lechenija [Russian ophthalmological journal]. Rossijskij oftal’mologicheskij zhurnal. 2012;5(2):55‑7 (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Merabishvili V., Merabishvili E. [Survival of patients with malignant tumors of the eye taking into account gender, age and histological structure of neoplasms]. Vyzhivaemost’ bol’nyh zlokachestvennymi novoobrazovanijami glaza s uchetom pola, vozrasta i gistologicheskoj struktury opukhole.j [Ophthalmology]. Oftal’mologija in Russia. 2016;13(1):38‑43. (In Russ.). DOI: http://dx.doi.org/10.18008/1816‑5095‑2016‑1</mixed-citation><mixed-citation xml:lang="en">Merabishvili V., Merabishvili E. [Survival of patients with malignant tumors of the eye taking into account gender, age and histological structure of neoplasms]. Vyzhivaemost’ bol’nyh zlokachestvennymi novoobrazovanijami glaza s uchetom pola, vozrasta i gistologicheskoj struktury opukhole.j [Ophthalmology]. Oftal’mologija in Russia. 2016;13(1):38‑43. (In Russ.). DOI: http://dx.doi.org/10.18008/1816‑5095‑2016‑1</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Stojuhina A.S., Chesalin I.P. [Survival rates for large choroidal melanomas]. Vyzhivaemost’ bol’nyh bol’shimi melanomami horioidei [Annals of ophthalmology]. Vestnik oftal’mologii. 2014;4:39‑44. (in Russ.). doi: 10.17116/oftalma2015131190‑94</mixed-citation><mixed-citation xml:lang="en">Stojuhina A.S., Chesalin I.P. [Survival rates for large choroidal melanomas]. Vyzhivaemost’ bol’nyh bol’shimi melanomami horioidei [Annals of ophthalmology]. Vestnik oftal’mologii. 2014;4:39‑44. (in Russ.). doi: 10.17116/oftalma2015131190‑94</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Kujala E., Makite T., Kivela T. Very long‑term prognosis of patients with malignant uveal melanoma. Invest. Ophthalmol. Vis.Sci. 2003:44:4651‑4659.</mixed-citation><mixed-citation xml:lang="en">Kujala E., Makite T., Kivela T. Very long‑term prognosis of patients with malignant uveal melanoma. Invest. Ophthalmol. Vis.Sci. 2003:44:4651‑4659.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report. 15. Arch Ophthalmol. 2001;119;670‑6.</mixed-citation><mixed-citation xml:lang="en">Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report. 15. Arch Ophthalmol. 2001;119;670‑6.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Gragoudas E.S., Egan K.M., Seddon J.M., et al. Survival of patients with metastases from uveal melanoma. Ophthalmology. 1991;98:383‑9.</mixed-citation><mixed-citation xml:lang="en">Gragoudas E.S., Egan K.M., Seddon J.M., et al. Survival of patients with metastases from uveal melanoma. Ophthalmology. 1991;98:383‑9.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Amirjan A.G., Saakjan S.V. [Prognostic factors for uveal melanoma]. Faktory prognoza uveal’noj melanomy. [Annals of ophthalmology]. Vestnik oftal’mologii. 2015;1:90‑94. (in Russ.). doi: 10.17116/oftalma2015131190‑94</mixed-citation><mixed-citation xml:lang="en">Amirjan A.G., Saakjan S.V. [Prognostic factors for uveal melanoma]. Faktory prognoza uveal’noj melanomy. [Annals of ophthalmology]. Vestnik oftal’mologii. 2015;1:90‑94. (in Russ.). doi: 10.17116/oftalma2015131190‑94</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Shhepetneva M.A., Kovalevskaja M.A., Efimova H.A. [Analysis of the incidence of melanoma of the choroid in the Voronezh Region]. Analiz zabolevaemosti melanomoj sosudistoj obolochki v Voronezhskoj oblasti. Sistemnyj analiz i upravlenie v biomedicinskih sistemah: zhurnal prakticheskoj i teoreticheskoj biologii i mediciny. [System analysis and management in biomedical systems: Journal of Practical and Theoretical Biology and Medicine]. 2008;7(3):640‑642. (in Russ.).</mixed-citation><mixed-citation xml:lang="en">Shhepetneva M.A., Kovalevskaja M.A., Efimova H.A. [Analysis of the incidence of melanoma of the choroid in the Voronezh Region]. Analiz zabolevaemosti melanomoj sosudistoj obolochki v Voronezhskoj oblasti. Sistemnyj analiz i upravlenie v biomedicinskih sistemah: zhurnal prakticheskoj i teoreticheskoj biologii i mediciny. [System analysis and management in biomedical systems: Journal of Practical and Theoretical Biology and Medicine]. 2008;7(3):640‑642. (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Furdova A., Slezak P., Chorvath M., Waczulikova I., Sramka M., Kralik G. No differences in outcome between radical surgical treatment (enucleation) and stereotactic radiosurgery in patients with posterior uveal melanoma. Neoplasma. 2010;57(4):377—381. doi:10.4149/neo_2010_04_377</mixed-citation><mixed-citation xml:lang="en">Furdova A., Slezak P., Chorvath M., Waczulikova I., Sramka M., Kralik G. No differences in outcome between radical surgical treatment (enucleation) and stereotactic radiosurgery in patients with posterior uveal melanoma. Neoplasma. 2010;57(4):377—381. doi:10.4149/neo_2010_04_377</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
